The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth
Cells · 28.02.2023 · 12 (5) · 775
DOI: 10.3390/cells12050775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 28.02.2023. Verfasst von Kishor Pant und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Hormel Institute, University of Minnesota, Austin, MN 55912, USA. Hauptthemen laut MEDLINE: Cisplatin, Cholangiocarcinoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hormel Foundation, POR CAMPANIA FESR 2014/2020, Italian Association for Cancer Research (AIRC).
Abstract (Originalsprache)
It is well established that Cholangiocarcioma (CCA) drug resistance plays a crucial role in the spread and survival of cancer cells. The major enzyme in the nicotinamide-adenine dinucleotide (NAD+)-mediated pathways, nicotinamide phosphoribosyltransferase (NAMPT), is essential for cancer cell survival and metastasis. Previous research has shown that the targeted NAMPT inhibitor FK866 reduces cancer cell viability and triggers cancer cell death; however, whether FK866 affects CCA cell survival has not been addressed before. We show herein that NAMPT is expressed in CCA cells, and FK866 suppresses the capacity of CCA cells to grow in a dose-dependent manner. Furthermore, by preventing NAMPT activity, FK866 significantly reduced the amount of NAD+ and adenosine 5′-triphosphate (ATP) in HuCCT1, KMCH, and EGI cells. The present study’s findings further show that FK866 causes changes in mitochondrial metabolism in CCA cells. Additionally, FK866 enhances the anticancer effects of cisplatin in vitro. Taken together, the results of the current study suggest that the NAMPT/NAD+ pathway may be a possible therapeutic target for CCA, and FK866 may be a useful medication targeting CCA in combination with cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
- Comparative Pathology Shared Resource, Masonic Cancer Center, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
- Telethon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy.
- Medical Genetics, Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.
ORCID-Profile: Kishor Pant, Estanislao Peixoto, Pietro Carotenuto, Brunella Franco, Lewis R Roberts, Sergio A Gradilone
Förderung
- Hormel Foundation
- POR CAMPANIA FESR 2014/2020
- Italian Association for Cancer Research (AIRC)
- AIRC
- European Union’s Horizon 2020
Zitieren
APA
Pant, K., Richard, S., Peixoto, E., Yin, J., Seelig, D. M., Carotenuto, P., Salati, M., Franco, B., Roberts, L. R., & Gradilone, S. A. (2023). The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth. Cells, 12(5), 775. https://doi.org/10.3390/cells12050775
Vancouver
Pant K, Richard S, Peixoto E, Yin J, Seelig DM, Carotenuto P, et al. The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth. Cells. 2023;12(5):775. doi:10.3390/cells12050775
BibTeX
@article{Pant2023,
author = {Pant, Kishor and Richard, Seth and Peixoto, Estanislao and Yin, Jun and Seelig, Davis M and Carotenuto, Pietro and Salati, Massimiliano and Franco, Brunella and Roberts, Lewis R and Gradilone, Sergio A},
title = {The NAMPT Inhibitor FK866 in Combination with Cisplatin Reduces Cholangiocarcinoma Cells Growth},
journal = {Cells},
year = {2023},
volume = {12},
number = {5},
pages = {775},
doi = {10.3390/cells12050775}
}
EUVIMED